Penicillamine is an orally-administered chelating agent used for treatment of heavy metal poisoning in poultry. Penicillamine is the preferred chelating agent for copper toxicosis, but can also be used for zinc, lead, and mercury.
Aspirin: The risk or severity of bleeding can be increased when Aspirin is combined with Penicillamine.
Chloramphenicol: The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Penicillamine.
Dexamethasone: The risk or severity of adverse effects can be increased when Penicillamine is combined with Dexamethasone.
Enalapril: The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Penicillamine.
Erythromycin: The excretion of Penicillamine can be decreased when combined with Erythromycin.
Iron Dextran: Iron Dextran can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ivermectin:The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Penicillamine.
Methylprednisolone: The risk or severity of adverse effects can be increased when Penicillamine is combined with Methylprednisolone.
Nystatin: The excretion of Penicillamine can be decreased when combined with Nystatin.
Prednisolone: The risk or severity of adverse effects can be increased when Penicillamine is combined with Prednisolone.
Propofol: The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Penicillamine.
Terbinafine: The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Penicillamine.
Trimethoprim: The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Penicillamine.
